抗中性粒细胞胞浆抗体相关性血管炎的心血管病变的研究进展

詹雅萍; 黄琴; 任昊; 杨敏

doi:10.13201/j.issn.1001-1439.2017.09.022

抗中性粒细胞胞浆抗体相关性血管炎的心血管病变的研究进展

- 南方医科大学南方医院风湿免疫科(广州, 510515)
基金项目:
南方医科大学科研启动计划 (No:PY2016N007)

南方医院院长基金 (No:2015C021)

详细信息

通讯作者: 任昊, E-mail:renhao67@aliyun.com

中图分类号: R364.5

收稿日期: 2017-01-21

Overview of cardiac involvement in ANCA-associated vasculitis

- Department of Rheumatology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China)〖ZK)〗

More Information

Corresponding author: REN Hao, E-mail: renhao67@aliyun.com

Received Date: 21 January 2017

摘要

摘要: 抗中性粒细胞胞浆抗体相关性血管炎(AAV)是一种系统性小血管炎,它可引起多器官损害(如急危重肾衰和肺出血),其病死率较高。然而,AAV的心血管受累较少见,其主要表现为血管狭窄、动脉瘤、主动脉夹层、主动脉破裂、主动脉反流等损害。在其3种临床分型中,嗜酸性肉芽肿血管炎的心脏损害最为常见,而在显微镜下多血管炎中心脏受累发生率最低。另外,血管炎的治疗过程(包括诱导期和维持期)中所用药物可能对患者在原发病基础上发生心血管病变产生影响。然而,对于AAV累及心血管的发病机制仍需进一步研究。
- 抗中性粒细胞胞浆抗体相关性血管炎 /
- 心血管疾病 /
- 药物
Abstract: Antineutrophil cytoplasmic antibody (ANCA) -associated vasculitis (AAV) is a systemic small-vessel vasculitis, which usually presents with multi-organ damage such as life-threatening kidney failure or pulmonary hemorrhage, causing a high mortality rate.However, cardiac involvement in AAV is rare and may present as arterial stenosis, aneurysmal disease, aortic dissection, aortic rupture, and aortic regurgitation.Of the three clinical types of AAV, cardiac involvement is the most common in eosinophilic granulomatosis (EGPA) while has been scarcely occurred in microscopic polyangiitis (MPA).Moreover, drugs used in the therapy of vasculitis including induction agents and maintenance agents may influence the risk of developing cardiovascular events in AAV patients.However, the pathogenesis of cardiac involvement in AAV requires further studies.
- anti-neutrophil cytoplasmic antibody-associated vasculitis /
- cardiovascular disease /
- drugs

HTML全文

参考文献(33)

[1]	JENETTE J C, FALK R J, BACON P A, et al.2012revised International Chapel Hill Consensus Conference Nomenclature of vasculitis[J].Arthritis Rheum, 2013, 65:1-11.
[2]	SADA K E, YAMAMURA M, HARIGAI M, et al.Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibodyassociated vasculitis in a nationwide, prospective, inception cohort study[J].Arthritis Res Ther, 2014, 16:R101-111.
[3]	MAHR A, KATSAHIAN S, VARET H, et al.French Vasculitis Study, the European Vasculitis, Revisiting the classification of clinical phenotypes of antineutrophil cytoplasmic antibody-associated vasculitis:a cluster analysis[J].Ann Rheum Dis, 2013, 72:1003-1010.
[4]	VILLIGER P M, GUILLEVIN L.Microscopicpolyangiitis:clinicalpresentation[J].Autoimmun Rev, 2010, 9:812-819.
[5]	HAZEBROEK M R, KEMNA M J, SCHALLA S, et al.Prevalence and prognostic relevance of cardiac involvement in ANCA-associated vasculitis:Eosinophilic granulomatosis with polyangiitis and granulomatosis with polyangiitis[J].Int J Cardiol, 2015, 199:170-179.
[6]	WILDE B, MERTENS A, ARENDS S J, et al.Endothelial progenitor cells are differentially impaired in ANCA-associated vasculitis compared to healthy controls[J].Arthritis Res Ther, 2016, 18:1-7.
[7]	MCKINNEY E F, WILLCOCKS L C, BROECKERV, et al.The immunopathology of ANCA-associated vasculitis[J].Semin Immunopathol, 2014, 36:461-478.
[8]	SHUAI Z W, LV Y F, ZHANG M M, et al.Clinical analysis of patients with myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis[J].Genet Mol Res, 2015, 14:5296-5303.
[9]	MCGEOCH L, CARETTE S, CUTHBERTSON D, et al.Cardiac involvement in granulomatosis with polyangiitis[J].J Rheumatol, 2015, 42:1209-1212.
[10]	SALAZAR-EXAIRE D, RAMOS-GORDILLO M, VE-LA-OJEDA J, et al.Silent Ischemic Heart Disease in a Patient with Necrotizing Glomerulonephritis due to Wegener's Granulomatosis[J].Cardiorenal Med, 2012, 2:218-224.
[11]	MISZALSKI-JAMKA T, SZCZEKLIK W, NYCZ K, et al.Two-dimensional speckle-tracking echocardiography reveals systolic abnormalities in granulomatosis with polyangiitis (Wegener's)[J].Echocardiography, 2012, 29:803-809.
[12]	LACOSTE C, MANSENCAL N, BEN M'RAD M, et al.Valvular involvement in ANCA-associated systemic vasculitis:a case report and literature review[J].BMC Musculoskelet Disord, 2011, 12:50.
[13]	PARRY S D, CLARK D M, CAMPBELL J.Coronary arteritis in Wegener's granulomatosis causing fatal myocardial infarction[J].Hosp Med, 2000, 61:284-285.
[14]	MISRA D P, CHOWDURY A C, EDAVALATH S, et al.Endocarditis:the great mimic of rheumatic diseases[J].Tropical Doctor, 2016, 46:180-186.
[15]	LANGLOIS V, LESOURD A, GIRSZYN N, et al.Antineutrophil Cytoplasmic Antibodies Associated With Infective Endocarditis[J].Medicine, 2016, 95:e2564.
[16]	REZA ARDALAN M, TRILLINI M.Infective endocarditis mimics ANCA associated glomerulonephritis[J].Caspian J Intern Med, 2012, 3:496-499.
[17]	GENDELMAN S, ZEFT A, SPALDING S J.Childhood-onset eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome):a contemporary single-center cohort[J].J Rheumatol, 2013, 40:929-935.
[18]	Dennert R M, van Paassen P, Schalla S, et al.Cardiac involvement in Churg-Strauss syndrome[J].Arthritis Rheum, 2010, 62:627-634.
[19]	MARMURSZTEJN J, GUILLEVIN L, TREBOSSENR, et al.Churg-Strauss syndrome cardiac involvement evaluated by cardiac magnetic resonance imaging and positron-emission tomography:aprospective study on20patients[J].Rheumatology (Oxford), 2013, 52:642-650.
[20]	SZCZEKLIK W, SOKOŁOWSKA B M, MASTAL-ERZ L, et al.QT dispersion in patients with ChurgStrauss syndrome[J].Kardiol Pol, 2011, 691143-1149.
[21]	MCKINNEY EF, WILLCOCKS LC, BROECKER V, et al.The immunopathology of ANCA-associated vasculitis[J].Semin Immunopathol, 2014, 36:461-478.
[22]	WALLACE Z S, LU N, UNIZONY S, et al.Improved survival in granulomatosis with polyangiitis:Ageneral population-based study[J].Semin Arthritis Rheum, 2015, 45:483-489.
[23]	MISZALSKI-JAMKA T, SZCZEKLIK W, SOKOŁO-WSKA B, et al.Noncorticosteroid immunosuppression limits myocardial damage and contractile dysfunction in eosinophilic granulomatosis with polyangiitis (ChurgStrauss syndrome)[J].J Am Coll Cardiol, 2015, 65:103-105.
[24]	TERRIER B, CHIRONI G, PAGNOUX C, et al.Factors associated with major cardiovascular events in patients with systemic necrotizing vasculitides:results of a longterm followup study[J].J Rheumatol, 2014, 41:723-729.
[25]	ZHOU F, LING C, GUO L, et al.Continuous low-dose cyclophosphamide and prednisone in the treatment of relapsed/refractory multiple myeloma with severe heart failure[J].Leuk Lymphoma, 2014, 55:2271-2276.
[26]	BULGARELLI A, LEITE A C JR, DIAS A A, et al.Anti-atherogenic effects of methotrexate carried by a lipid nanoemulsion that binds to LDL receptors in cholesterol-fed rabbits[J].Cardiovasc Drugs Ther, 2013, 27:531-539.
[27]	AHLEHOFF O, SKOV L, GISLASON G, et al.Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis:5-year followup of a Danish nationwide cohort[J].J Eur Acad Dermatol Venereol, 2015, 29:1128-1134.
[28]	FERNANDEZ-NEBRO A, MARENCO J L, LÓPEZ-LONGO F, Et al.The effects of rituximab on the lipid profile of patients with active systemic lupus erythematosus:Results from a nationwide cohort in Spain (LESIMAB)[J].Lupus, 2014, 23:1014-1022.
[29]	VAN SIJL A M, VAN DER WEELE W, NURMO-HAMED M T.Myocardial infarction after rituximab treatment for rheumatoid arthritis:Is there a link?[J].Curr Pharm Des, 2014, 20:496-499.
[30]	ROUBILLE C, RICHER V, STARNINO T, et al.The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis:a systematic review and meta-analysis[J].Ann Rheum Dis, 2015, 74:480-489.
[31]	ZANOLI L, RASTELLI S, INSERRA G, et al.Increased arterial stiffness in inflammatory bowel diseases is dependent upon inflammation and reduced by immunomodulatory drugs[J].Atherosclerosis, 2014, 234:346-351.
[32]	SPAGNOLETTI G, CITTERIO F, FAVI E, et al.Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens:tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine[J].Transplant Proc, 2009, 41:1175-1177.
[33]	CUERVAS-MONS V, HERRERO J I, GOMEZ M A, et al.Impact of tacrolimus and mycophenolate mofetil regimen vs.a conventional therapy with steroids on cardiovascular risk in liver transplant patients[J].Clin Transplant 2015, 29:667-677.